Publication | Closed Access

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

ObesityDiabetes ManagementMedicineDiabetesClinical TrialsPharmacotherapyStep 2Diabetes MellitusPharmacology